186 related articles for article (PubMed ID: 20110726)
1. Prevalence of polycystic ovary syndrome and related disorders in mexican women.
Moran C; Tena G; Moran S; Ruiz P; Reyna R; Duque X
Gynecol Obstet Invest; 2010; 69(4):274-280. PubMed ID: 20110726
[TBL] [Abstract][Full Text] [Related]
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China.
Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W
J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
[TBL] [Abstract][Full Text] [Related]
7. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne.
Kelekci KH; Kelekci S; Incki K; Ozdemir O; Yilmaz B
Int J Dermatol; 2010 Jul; 49(7):775-9. PubMed ID: 20618496
[TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome.
Leerasiri P; Wongwananuruk T; Indhavivadhana S; Techatraisak K; Rattanachaiyanont M; Angsuwathana S
J Obstet Gynaecol Res; 2016 Jun; 42(6):678-83. PubMed ID: 26890011
[TBL] [Abstract][Full Text] [Related]
9. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors.
Sanchón R; Gambineri A; Alpañés M; Martínez-García MÁ; Pasquali R; Escobar-Morreale HF
Hum Reprod; 2012 Apr; 27(4):1209-16. PubMed ID: 22343706
[TBL] [Abstract][Full Text] [Related]
11. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study.
Skiba MA; Bell RJ; Herbert D; Garcia AM; Islam RM; Davis SR
Hum Reprod; 2021 May; 36(6):1611-1620. PubMed ID: 33846715
[TBL] [Abstract][Full Text] [Related]
12. In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study.
Koch T; Doherty DA; Dickinson JE; Juul A; Hart R; Bräuner EV; Hickey M
Psychoneuroendocrinology; 2021 Mar; 125():105104. PubMed ID: 33352473
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study.
Tehrani FR; Rashidi H; Azizi F
Reprod Biol Endocrinol; 2011 Nov; 9():144. PubMed ID: 22044512
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
16. Ovarian surgery for symptom relief in women with polycystic ovary syndrome.
Lepine S; Jo J; Metwally M; Cheong YC
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD009526. PubMed ID: 29125183
[TBL] [Abstract][Full Text] [Related]
17. Polycystic ovaries and associated clinical and biochemical features in young women.
Michelmore KF; Balen AH; Dunger DB; Vessey MP
Clin Endocrinol (Oxf); 1999 Dec; 51(6):779-86. PubMed ID: 10619984
[TBL] [Abstract][Full Text] [Related]
18. [Polycystic ovary syndrome: is there a rise in the prevalence?].
Carmona-Ruiz IO; Saucedo-de la Llata E; Moraga-Sánchez MR; Romeu-Sarró A
Ginecol Obstet Mex; 2015 Dec; 83(12):750-9. PubMed ID: 27290799
[TBL] [Abstract][Full Text] [Related]
19. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne.
Timpatanapong P; Rojanasakul A
J Dermatol; 1997 Apr; 24(4):223-9. PubMed ID: 9164062
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
Yildiz BO; Bozdag G; Yapici Z; Esinler I; Yarali H
Hum Reprod; 2012 Oct; 27(10):3067-73. PubMed ID: 22777527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
